Equities Focus

Equities Focus | Healthcare 2nd March 2020
2nd March 2020 Atheneum Team
2nd March 2020

Key Atheneum Experts

Former CMO – CoCrystal
VP of Global Commercial Operations – Reata (rival)
Director of Medical Affairs – Reata (rival)

Key Information

HQ – US
Operations – N/A

Cocrystal Pharma jumped 63.1% premarket on 25th Feb after nearly tripling its share price on 24th Feb. The hike is in response to the announcement that it has entered into a new licensing agreement with Kansas State University, which has granted Cocrystal exclusive royalty and property rights for antiviral compounds for the treatment of coronavirus. Stocks have risen 112% in the past 30 days, but have declined 54% over the last 52 weeks.

Key Atheneum Experts

Former Associate Director – Moderna
Former Head of Development – Moderna
Principal Scientist – Therapeutics (rival)

Key Information

HQ – US
Operations – N/A

Moderna claim to have released the first batch of human use vaccines for the coronavirus. They have been shared with the National Institute of Allergy and Infectious Disease for phase 1 studies. The company did not reveal profitability expectations for the vaccine during their Q4 investor call. Moderna have new vaccines being delivered; CMV-an infection leading to birth defects. Stocks are up 26% in past 30 days.

Key Atheneum Experts

Former Strategic Director – Co-Diagnostics
Product Manager – Thermofisher (rival)
Global Laboratory Operations Manager – Siemens Healthineers (rival)

Key Information

HQ – US
Operations – N/A

Co-Diagnostics who has a patented platform for the development of molecular diagnostic tests; have recently announced their coro-navirus testing platform has achieved regulatory clearance for use in the US, European and global health communities. Stocks rose a 306% in the past 30 days, and 1003% over the last 52 weeks.

Key Atheneum Experts

Former Senior Medical Director – CVS
Former Marketing Director – CVS
Former Regional VP Operations – Rite Aid Corp (rival)

Key Information

HQ – US
Operations – US, Columbia, Puerto Rico

CVS faces challenges from Walmart after announcing their low price alternative clinical service. The new Walmart Health Centres can offer budget medical check ups, teeth cleaning services and counselling, all via an online booking or walk in. Walmart intends to break into the United States large health market, and have made their clinics their top priority. As a result CVS stocks are down 13% in the past 30 days, but a 1.8% increase over the last 52 weeks.

Key Atheneum Experts

Former Corporate Marketing Manager – APT
Former Marketing Manager – Praxisdienst (rival)
Project Manager – Praxisdienst (rival)

Key Information

HQ – Canada
Operations – Global

APT sell protective apparel products; earlier in the month their sales for facemasks soared to be worth over $10.4M due to in-creasing demand in response to the coronavirus outbreak. APT’s reported an annual $46.7M revenue, but $0.6M fall in net income; due to a change in product mix and a loss of tariff free status for their Disposable Protecitve Apparel. The shares are up 213% in the past 30 days, and up 445% over the last 52 weeks.

To learn more please email: yashar.jedari@atheneum-partners.com